Edit
Momenta Pharmaceuticals
https://www.momentapharma.com/home/default.aspxLast activity: 18.09.2026
Active
Momenta is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases. Our scientific foundation is based on a deep understanding of immune biology and disease analytics. This work, together with our protein engineering and antibody design expertise has led to the development of a number of novel therapeutics for immune-mediated diseases with high unmet need.
Location: United States, Massachusetts, Cambridge
Employees: 201-500
Founded date: 2001
Investors 4
| Date | Name | Website |
| - | Old Silver... | oldsilverv... |
| 18.09.2026 | Omega Fund... | omegafunds... |
| - | Atlas Vent... | atlasventu... |
| - | Cardinal P... | cardinalpa... |
Mentions in press and media 9
| Date | Title | Description |
| 02.09.2020 | August M&A: Netcapital merges with ValueSetters, Kronos and Ultimate unveil rebrand | This wasn't a particularly hot month for M&A activity in Boston, with a handful of deals crowded toward the end of the month. But we still saw some major moves. Of note, Netcapital agreed to merge with ValueSetters, its longtime partner... |
| 19.08.2020 | Momenta Pharmaceuticals spikes 69% after agreeing to $6.5 billion Johnson & Johnson takeover | Momenta Pharmaceuticals surged as much as 69% on Wednesday after reaching an agreement to be acquired by Johnson & Johnson. The deal values Momenta at $52.50 per share, a 70.4% premium to its Wednesday close. The acquisition will cost J... |
| 13.02.2018 | Novartis, Momenta grab a delayed FDA OK for blockbuster Copaxone knockoff | After a long delay, Momenta $MNTA and Novartis $NVS have finally received an FDA green light for its Copaxone copycat, catching up with Mylan in slicing shares of the multiple sclerosis market from struggling Teva. Sa... |
| 21.02.2017 | Bad news for Momenta and Pfizer is a much-needed blessing for Teva | File this under “reversal of fortunes.” Late last Friday, Momenta Pharmaceuticals disclosed that a Pfizer plant contracted to make a generic version of a best-selling multiple sclerosis medicine was slapped with a warning letter by the US F... |
| 27.09.2016 | Shire punts late-stage biosimilars of Humira and Enbrel back to Momenta, Coherus | Momenta CEO Craig Wheeler Just days after Amgen won an FDA approval for the first biosimilar of AbbVie’s Humira, Shire $SHPG has decided to throw away its partnership rights in a rival program now in Phase III. Shire sim... |
| 31.07.2013 | Pharma firm bets sialic acid could help explain link between diet and inflammatory diseases | It’s simultaneously developing two products: an antibody targeting solid tumors including ovarian, breast and colon cancers, and a nutritional supplement designed to tame the immune response to nonhuman sialic acid. Researchers have been ex... |
| 13.08.2009 | Turmoil at the FDA? — MedCity Morning Read, Aug. 13, 2009 | Momenta says the co-authored paper represents a conflict of interest and asked that Woodcock excuse herself from the blood thinner approval process. The FDA says it’s aware of the complaint, but Woodcock had not removed herself from the pr... |
| - | Turmoil at the FDA? — MedCity Morning Read, Aug. 13, 2009 | WASHINGTON, D.C. — The inspector general of the U.S. Department of Health and Human Services is investigating a conflict-of-interest allegation involving the nation’s top drug regulator, Janet Woodcock, according to the U.S. Food and Drug A... |
| - | Pharma firm bets sialic acid could help explain link between diet and inflammatory diseases | A syndicate of East Coast angel investors pieced together $1 million to help a bicoastal startup commercialize products it thinks may prevent disease-causing inflammation linked to consumption of animal products such as red meat and dairy. ... |